- Brands
- Offerings
- Diagnostic Panels
- Knowledge Center
- Diagnostics
Core Laboratory
Core Laboratory
Webinars
Access on demand presentations led by subject matter experts and Abbott key opinion leaders to gain insight into industry trends, medical discoveries, healthcare technologies and much more.
Watch now. Visit us frequently for new content.
IMPACT OF GLOBAL VIRAL SURVEILLANCE ON DIAGNOSTIC TOOLS
When disease-causing viruses (e.g. hepatitis B) mutate, there is a risk of being unable to detect them for diagnosis and monitoring, as well as the risk that the treatment response to current medications may be lessened. Therefore, viral genetic diversity has the potential to impact a vast number of healthcare touchpoints.
Abbott is constantly searching for new ways to improve people's health. A critical success factor involves monitoring retroviruses and hepatitis viruses from around the globe with a surveillance program, to help ensure laboratory tests continue to accurately detect divergent virsuses, regardless of where they are acquired. Since 1994, Abbott's Global Viral Surveillance Program has been at the forefront of viral surveillance continually evolving to impact the development of next generation solutions.
Speaker
Gavin A. Cloherty, PHD
Head of Infectious Disease Research, Abbott Diagnostics
Gavin A. Cloherty, graduated from the National University of Ireland, Galway, where he received his Ph.D in molecular biology and a Bachelor of Science in microbiology and zoology. He provides scientific leadership in the area of infectious disease diagnostics by leading groundbreaking clinical studies on hepatitis and HIV. As one of the top experts in the field, his innovative research is changing the way infectious diseases are being diagnosed to help improve patient outcomes.
Gavin has 20 years of experience with Abbott and leads a team of scientists in the study of HIV and hepatitis related discoveries, Gavin leads a team that recently identified unique hepatitis E recombinant strains in humans, uncovered unexpectedly high prevalence of hepatitis Delta in countries such as Cameroon, and identified strains of the newly discovered HPgV-2 in samples from around the world.
Throughout his career Gavin has published numerous abstracts, posters, and manuscripts. He has established numerous partnerships with commercial organizations, ministries of health and government agencies, including the Centers for Disease Control and Prevention (CDC). He is a member of numerous professional and scientific societies, including the International AIDS Society and the American Association for the Study of Liver Disease.
Gavin has 20 years of experience with Abbott and leads a team of scientists in the study of HIV and hepatitis related discoveries, Gavin leads a team that recently identified unique hepatitis E recombinant strains in humans, uncovered unexpectedly high prevalence of hepatitis Delta in countries such as Cameroon, and identified strains of the newly discovered HPgV-2 in samples from around the world.
Throughout his career Gavin has published numerous abstracts, posters, and manuscripts. He has established numerous partnerships with commercial organizations, ministries of health and government agencies, including the Centers for Disease Control and Prevention (CDC). He is a member of numerous professional and scientific societies, including the International AIDS Society and the American Association for the Study of Liver Disease.
LEARNING OBJECTIVES
- Understand the evolution of the Global Viral Surveillance Program and find out what's new
- Discover the impact of viral surveillance on past, present and future laboratory diagnostic tools
- Understand how you can get involved in the program
WHO SHOULD WATCH
- Laboratorians
- Clinicians
HEPATITIS C ELIMINATION STARTS WITH DIAGNOSIS
How do you eliminate a disease that 95% of people don't know they have?
Hepatitis C is called a silent killer because it often goes unnoticed for decades until serious liver damage has occurred. Diagnosing infected individuals is the first step in preventing the spread of Hepatitis C to others, in linking patients to curative therapies, and in driving overall awareness.
A healthier future without Hepatitis C is now possible, through innovations in science and technology. Watch the educational webinar to learn how clinical laboratory advancements can help make elimination a reality.
Speaker
Jean-Michel Pawlotsky
Professor of Medicine at the University of Paris-Est.
Prof. Jean-Michel Pawlotsky, MD, PhD is a Professor of Medicine at the University of Paris-Est., Director of the National Reference Center for Viral Hepatitis B, C, and D, Director of the Department of Virology at the Henri Mondor University Hospital in Créteil France, Director of the Academic Department Viruses, Immunity, and Cancers.
LEARNING OBJECTIVES
- Discuss the importance of the clinical laboratory in reaching the World Health Organization’s elimination goals
- Understand recent guideline advancements that support Hepatitis C elimination
- Describe simplified diagnostic processes that support improved access to care
WHO SHOULD WATCH
- Laboratorians
- Clinicians
Event: IfCC Euromedlab 2019
TACKLING HEPATITIS C ELIMINATION —
ARE WE FLYING BLIND?
The world health organization (WHO) published its first global health sector strategy on viral hepatitis in May 2016. The following year WHO reported that only about 20% of people with chronic Hepatitis C virus (HCV) were thought to be aware of their disease, and only a small fraction of those diagnosed are receiving treatment. WHO describes these and global Hepatitis B virus (HBV) estimates as “preliminary”. To remedy the situation, national governments need to do much more to meet their monitoring responsibilities in relation to viral hepatitis, a group of diseases that claims more lives annually than HIV or malaria do.
Without reliable information about the extent of the problem, and about the impact of interventions to mitigate the problem, it is not possible for health systems to determine how to best allocate their always-limited resources. Large knowledge gaps regarding disease epidemiology and intervention coverage may seem to be characteristic of resource-limited countries.
However, some of the most affluent countries in the world are unprepared to carry out the kind of evidence-based decision making that will be required to achieve the goal of eliminating viral hepatitis as a public health threat by 2030. This problem is partly reflective of how HCV infection manifests – often with a decades-long asymptomatic period during which liver deterioration progresses unnoticed. Yet monitoring the disease is not the greatest obstacle to progress against the global the epidemic. The greatest obstacle is government inaction, as reflected by the fact that globally less than half of all WHO member states report having viral hepatitis strategies or plans and only 12 are on track for elimination. Eliminating HCV as a public health threat is feasible – but only with greater attention to health systems. This presentation will review the main components of a people-centred health systems approach to viral hepatitis elimination.
Speaker
Dr. Jeffrey Lazarus
Hospital Clínic, University of Barcelona, Spain
LEARNING OBJECTIVES
- The laboratory has a central role in the health care system, and often provides critically important information to the health care professional.
- In this workshop, presented at EuroMedLab 2019, approaches to ensure HCV elimination are discussed. You will learn about novel approaches to meet WHO targets for HCV elimination.
WHO SHOULD WATCH
- Laboratorians
- Clinicians
RISK STRATIFICATION OF APPARENTLY HEALTHY POPULATION WITH ARCHITECT STAT HIGH SENSITIVE TROPONIN-I
In this webinar you will hear about a recently CE marked application for ARCHITECT STAT High Sensitive Troponin I, that aids in providing greater accuracy for estimation of risk for future cardiac events in apparently healthy people, when used in conjunction with clinical and diagnostics findings. Risk is classified as low, moderate or elevated and use of ARCHITECT STAT High Sensitive Troponin I, is supported by a large body of evidence. This simple blood test can aid in earlier intervention for high risk patients and may avoid unnecessary tests and treatments in low risk patients. ARCHITECT STAT High Sensitive Troponin I, is well known to many through its use in Emergency Departments where it has been trusted for many years to rule in or rule out Myocardial Infarction. This latest application sets the stage to support tackling the cardiovascular disease burden through prevention.
Speaker
Gillian Murtagh, MD
Associate Medical Director, Abbott Diagnostics
Dr. Murtagh is Associate Medical Director of Medical and Scientific Affairs for Abbott Diagnostics. Dr. Murtagh directs and implements clinical research activities, internal and external educational programs and business development projects in the cardiac space. Dr. Murtagh received her MD from Trinity College Dublin in 2003 before completing residency in Internal Medicine and specialty training in Cardiology (Advanced Cardiovascular Imaging and Cardio-Oncology at Northwestern Memorial and the University of Chicago). Dr. Murtagh has been involved in cardiovascular biomarker research for over ten years. She was co-chair of the ACC Working Group in Cardio-Oncology and has authored and co-authored multiple publications on biomarkers and imaging. She joined Abbott Diagnostics Division as Associate Medical Director in 2015.
LEARNING OBJECTIVES
- Understand the limitations of current risk assessment tools
- Understand how addition of ARCHITECT STAT High Sensitive Troponin I into assessment algorithms can assist in predicting risk
- Understand the body of evidence
WHO SHOULD WATCH
- Laboratorians
- Endocrinologists
- Clinicians
- Metabolic Specialists
RELATED PAGES
Event: Esc preventive cardiology 2021
emerging role of cardiac biomarkers in cardiovascular risk stratification
In this webinar you can learn more about how the emerging role of cardiac biomarkers in cardiac risk stratification and how taking a patient centric approach through the additional use of high-sensitivity troponin I, in conjunction with other clinical diagnostic findings, can guide treatment and to help improve patient outcomes.
Speakers
Dr. Wolfgang Koenig
Dr. Luis Liete
Dr. Anoop Shah
Dr. Wolfgang Koenig, MD, FRCP, FACC, FAHA, FESC is a Professor of Cardiology. A former Director of the WHO-MONICA Augsburg Myocardial Infarction Registry, he has held multiple clinical positions at the University of Ulm Medical Center. In April 2015 he joined the Deutsches Herzzentrum München, where he is the Head of the Cardiometabolic Unit.
Dr. Luis Liete is currently an Interventional Cardiologist at CHUC (Coimbra, Portugal).
Dr. Anoop Shah is affiliated with London School of Hygiene and Tropical Medicine, London. His main research aims are to understand the epidemiological trends in the incidence and diagnosis of common cardiovascular pathologies. He is involved in multi-center cluster randomized clinical trials using 'big data' to evaluate how changes in health systems can improve outcomes in patients with cardiovascular disease. He maintains a keen research interest in global cardiovascular health especially in low- and middle-income nations.
LEARNING OBJECTIVES
- Learn about the benefits of using cardiac biomarkers to better stratify patients’ risk of a future cardiac event
- Understand limitations of classical risk stratification models and emphasizing the importance of customizing the approach to prevention of CVD
WHO SHOULD WATCH
- Cardiologists
- Primary Care Physicians
- Laboratorians
- Chief Medical Officer
RELATED PAGES
Explore
Build key laboratory competencies and explore topics from various disciplines with our learning guides.
Find the latest information in laboratory science, therapeutic areas and Abbott innovation.
Watch the webinar to hear from experts how you can realize the value within and beyond your laboratory walls with a TVO approach.